Digest Network Come funziona
Network
/
Società
Pe
Non verificato

PepGen Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

31 comunicati stampa

Guarda tutti i comunicati
12/11/2025
Industria
Associazioni/Professionisti
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
PepGen to Participate in Upcoming Investor Conferences
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
02/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Industria
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
26/09/2025
Finanza
Biotecnologia
Farmaceutica
Sanità
Salute
Associazioni/Professionisti
Medicina - Varie
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
25/09/2025
Associazioni/Professionisti
Salute
Finanza
Medicina - Varie
Farmaceutica
Biotecnologia
PepGen Announces Pricing of $100 Million Public Offering
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
24/09/2025
Biotecnologia
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
PepGen Announces Proposed Public Offering
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
24/09/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
07/08/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0
28/05/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
Fonte
PepGen Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0